JP2008500277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500277A5 JP2008500277A5 JP2006552536A JP2006552536A JP2008500277A5 JP 2008500277 A5 JP2008500277 A5 JP 2008500277A5 JP 2006552536 A JP2006552536 A JP 2006552536A JP 2006552536 A JP2006552536 A JP 2006552536A JP 2008500277 A5 JP2008500277 A5 JP 2008500277A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- days
- human immunoglobulin
- administration
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 10
- 102000018358 immunoglobulin Human genes 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/778,915 US20050180979A1 (en) | 2004-02-13 | 2004-02-13 | Anti-EpCAM immunoglobulins |
| US10/778,915 | 2004-02-13 | ||
| PCT/EP2005/001307 WO2005080428A2 (en) | 2004-02-13 | 2005-02-09 | Anti-epcam immunoglobulins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008500277A JP2008500277A (ja) | 2008-01-10 |
| JP2008500277A5 true JP2008500277A5 (https=) | 2008-04-03 |
| JP5220315B2 JP5220315B2 (ja) | 2013-06-26 |
Family
ID=34838270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552536A Expired - Fee Related JP5220315B2 (ja) | 2004-02-13 | 2005-02-09 | 抗ＥｐＣＡＭ免疫グロブリン |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20050180979A1 (https=) |
| EP (2) | EP2107071A3 (https=) |
| JP (1) | JP5220315B2 (https=) |
| KR (1) | KR101236224B1 (https=) |
| CN (1) | CN1976951B (https=) |
| AT (1) | ATE437186T1 (https=) |
| AU (1) | AU2005215874B2 (https=) |
| BR (1) | BRPI0507660A (https=) |
| CA (1) | CA2555694C (https=) |
| DE (1) | DE602005015544D1 (https=) |
| DK (1) | DK1713830T3 (https=) |
| EA (1) | EA011951B1 (https=) |
| ES (1) | ES2328159T3 (https=) |
| IL (1) | IL177069A (https=) |
| MX (1) | MXPA06008942A (https=) |
| NO (1) | NO339364B1 (https=) |
| NZ (1) | NZ549125A (https=) |
| PL (1) | PL1713830T3 (https=) |
| PT (1) | PT1713830E (https=) |
| SI (1) | SI1713830T1 (https=) |
| UA (1) | UA87128C2 (https=) |
| WO (1) | WO2005080428A2 (https=) |
| ZA (1) | ZA200606083B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004068110A2 (en) | 2003-01-24 | 2004-08-12 | University Of Utah | Methods of predicting mortality risk by determining telomere length |
| WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
| CA2638040A1 (en) * | 2006-02-09 | 2007-08-16 | Micromet Ag | Treatment of metastatic breast cancer |
| EP1865001A1 (en) * | 2006-06-08 | 2007-12-12 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Specific protease inhibitors and their use in cancer therapy |
| ATE509956T1 (de) * | 2006-06-08 | 2011-06-15 | Helmholtz Zentrum Muenchen | Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie |
| EP2142570B1 (en) * | 2007-04-04 | 2011-06-15 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Anti-epcam antibody and uses thereof |
| US9689028B2 (en) | 2008-12-22 | 2017-06-27 | University Of Utah Foundation | Monochrome multiplex quantitative PCR |
| AU2010295172B2 (en) * | 2009-09-21 | 2016-08-04 | Ranju Ralhan | Methods and compositions for the diagnosis and treatment of thyroid cancer |
| TWI485161B (zh) * | 2012-03-02 | 2015-05-21 | 中央研究院 | 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法 |
| CN103387989B (zh) * | 2012-09-24 | 2016-05-18 | 厦门大学 | 上皮细胞粘附分子的核酸适体EpCAM D及其制备方法 |
| EP2999800B1 (en) | 2013-05-22 | 2019-09-25 | Telomere Diagnostics Inc. | Measures of short telomere abundance |
| CN103275226B (zh) * | 2013-06-09 | 2017-08-29 | 中国科学技术大学 | 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用 |
| ES3012974T3 (en) * | 2014-01-08 | 2025-04-10 | Univ Leland Stanford Junior | Targeted therapy for lung cancer |
| US9944978B2 (en) | 2014-12-30 | 2018-04-17 | Telomere Diagnostics, Inc. | Multiplex quantitative PCR |
| ES2873846T5 (en) * | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| US20190262397A1 (en) | 2016-07-26 | 2019-08-29 | Tessa Therapeutics Pte. Ltd. | Chimeric antigen receptor |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5853697A (en) * | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
| BRPI9809391B8 (pt) * | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| PT1383785E (pt) * | 2001-05-03 | 2011-06-28 | Merck Patent Gmbh | Anticorpo recombinante específico de tumores e utilização deste |
| US20030175268A1 (en) * | 2002-01-11 | 2003-09-18 | Saint-Remy Jean-Marie R. | Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome |
| WO2003099205A2 (en) * | 2002-05-20 | 2003-12-04 | Abgenix, Inc. | Treatment of renal carcinoma using antibodies against the egfr |
-
2004
- 2004-02-13 US US10/778,915 patent/US20050180979A1/en not_active Abandoned
-
2005
- 2005-02-09 PL PL05707293T patent/PL1713830T3/pl unknown
- 2005-02-09 CA CA2555694A patent/CA2555694C/en not_active Expired - Fee Related
- 2005-02-09 EP EP09165284A patent/EP2107071A3/en not_active Withdrawn
- 2005-02-09 WO PCT/EP2005/001307 patent/WO2005080428A2/en not_active Ceased
- 2005-02-09 JP JP2006552536A patent/JP5220315B2/ja not_active Expired - Fee Related
- 2005-02-09 EA EA200601386A patent/EA011951B1/ru not_active IP Right Cessation
- 2005-02-09 AU AU2005215874A patent/AU2005215874B2/en not_active Ceased
- 2005-02-09 NZ NZ549125A patent/NZ549125A/en not_active IP Right Cessation
- 2005-02-09 DK DK05707293T patent/DK1713830T3/da active
- 2005-02-09 SI SI200530759T patent/SI1713830T1/sl unknown
- 2005-02-09 AT AT05707293T patent/ATE437186T1/de active
- 2005-02-09 UA UAA200608985A patent/UA87128C2/ru unknown
- 2005-02-09 DE DE602005015544T patent/DE602005015544D1/de not_active Expired - Lifetime
- 2005-02-09 EP EP05707293A patent/EP1713830B1/en not_active Expired - Lifetime
- 2005-02-09 ES ES05707293T patent/ES2328159T3/es not_active Expired - Lifetime
- 2005-02-09 PT PT05707293T patent/PT1713830E/pt unknown
- 2005-02-09 KR KR1020067016339A patent/KR101236224B1/ko not_active Expired - Fee Related
- 2005-02-09 US US10/589,450 patent/US20070274982A1/en not_active Abandoned
- 2005-02-09 CN CN2005800099764A patent/CN1976951B/zh not_active Expired - Fee Related
- 2005-02-09 BR BRPI0507660-9A patent/BRPI0507660A/pt not_active Application Discontinuation
- 2005-02-09 MX MXPA06008942A patent/MXPA06008942A/es active IP Right Grant
-
2006
- 2006-07-21 ZA ZA200606083A patent/ZA200606083B/en unknown
- 2006-07-25 IL IL177069A patent/IL177069A/en not_active IP Right Cessation
- 2006-09-13 NO NO20064136A patent/NO339364B1/no not_active IP Right Cessation
-
2012
- 2012-06-01 US US13/486,749 patent/US20120294873A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008500277A5 (https=) | ||
| ES2981830T3 (es) | Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres | |
| JP2007500236A5 (https=) | ||
| JP2009506790A5 (https=) | ||
| JP2020515578A5 (https=) | ||
| JP2006522830A5 (https=) | ||
| JP2004501101A5 (https=) | ||
| JP2013533858A5 (https=) | ||
| RU2020115713A (ru) | Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения | |
| RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
| JP2014515763A5 (https=) | ||
| JP2012518686A5 (https=) | ||
| JP2009505676A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| RU2013142004A (ru) | Конъюгаты "антитело-лекарственное средство" | |
| JP2011103891A5 (https=) | ||
| JP2021513536A5 (https=) | ||
| JP2021523170A5 (https=) | ||
| RU2007145489A (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
| JP2015517523A5 (https=) | ||
| JP2018512402A5 (https=) | ||
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| WO2021129616A1 (zh) | 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法 | |
| JP2008154589A5 (https=) | ||
| RU2011130522A (ru) | Моноклональное антитело против hcv в качестве лекарственного средства для терапевтического лечения и профилактики инфекций hcv |